Multiple Myeloma Excellence Forum

Multiple Myeloma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Exploring the Current Treatment Landscape for Patients With Extramedullary MM

10/29/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Saad Usmani, MD, discusses optimal strategies and the current treatment landscape for patients with extramedullary multiple myeloma.

At the 2024 Lymphoma, Leukemia &...

10/29/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Identifying Unmet Clinical Needs in Treating Patients With Extramedullary MM

10/28/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.

At the 2024 Lymphoma, Leukemia &...

10/28/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Exploring the Immune Microenvironment in Multiple Myeloma Treatment

10/25/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...

At the 2024 Lymphoma, Leukemia &...

10/25/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Treatment Options for When Immune Therapies Fail Among Patients With R/R MM

10/24/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with  R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...

At the 2024 Lymphoma, Leukemia &...

10/24/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Updates in Novel and Cellular Therapies for Patients With R/R Multiple Myeloma

09/12/2024

Jonathan Kaufman, MD, discusses recent updates for treating patients with relapsed/refractory multiple myeloma with new and immune cellular therapies.

Jonathan Kaufman, MD, discusses...

09/12/2024

Oncology

Oncology Advances: Long-Term Efficacy and Safety Results on Talquetamab Treatment for Patients With R/R Multiple Myeloma

Videos

Should Additional BCMA Therapy be Utilized After Prior BCMA Treatment for Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Should Stem Cell Transplantation be Suggested for Older Patients With Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Benefits of Utilizing CAR-T in Later Lines of Therapy for Patients With Multiple Myeloma

07/28/2024

At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.

At the 2024 Great Debates &...

07/28/2024

Oncology

Videos

Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?

07/28/2024

At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...

At the 2024 Great Debates &...

07/28/2024

Oncology

Section Editor

Shaji Kumar, MD

Mayo Clinic, Rochester, Minnesota

Multiple Myeloma Excellence Forum

Section Editor

Specialties

Events

Year Round Education

HMP Global Products